An interview with Kristian Villumsen, a SVP at Coloplast, on how ReD helped the healthcare company innovate.

Pharmaceutical companies should take a closer look at how they create value. In a world of value-based health care, the answer goes beyond developing a new drug.

As medical understanding around body weight and related medical problems has increased, obesity has become a healthcare concern as well as an aesthetic one.

To understand and diagnose an illness requires acknowledging the ecology in which it takes place and collecting multiple perspectives.

Understanding cultural differences is good for drug companies’ top lines, and also for pushing the boundaries of medical science.

With the new reality of pharmaceutical R&D, companies must deliver impact and value. This paper explores how ethnographic research can fill that role in early stages of pharmaceutical clinical trials.

How understanding the social, psychological, and emotional experience of psoriasis is fueling the pharmaceutical industry.

ReD facilitated Coloplast’s transition to compliance with a more micro-level approach to innovation.

ReD conducted Novo Nordisk’s first study around the emotional experience of patients living with diabetes.

ReD helped Coloplast understand a key insight about its users: that not all bodies are shaped the same.

Pharma companies are taking steps toward "patient-centric" healthcare by using patient insights to guide drug development and clinical trials.

In business thinking, ‘core competencies’ have long been seen as the critical factor that distinguishes great from good. Great companies have strong core competencies that they constantly leverage and develop. On the other hand, companies who do not understand their own strengths and weaknesses cannot execute at the highest proficiency.